LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024
Image: The Chronus Health platform is being demonstrated at ADLM 2024 (Photo courtesy of Chronus Health)
Image: The Chronus Health platform is being demonstrated at ADLM 2024 (Photo courtesy of Chronus Health)

Chronus Health (Fremont, CA, USA) is showcasing its innovative platform powered by electrical sensing-based blood testing technology at the ADLM 2024 conference taking place in Chicago from July 28 to August 1.

Chronus has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics. This technology will reduce the time to diagnosis and lower overall healthcare costs since blood samples are analyzed on-site rather than sent to central labs for analysis. Chronus’ platform can uniquely support cell counting, chemistry assays (electrolytes, small molecules, and proteins), and immunoassays (proteins). This comprehensive solution, often regarded as the “holy grail” of diagnostics, has remained elusive until now, as past attempts to miniaturize existing technologies have lacked technical feasibility and cost-effectiveness.

The world’s first real-time electrical blood test system offers significant advantages in cost, size, and simplicity through the use of electrical sensors that facilitate miniaturization and reduce complexity. By leveraging a proprietary electrical sensing approach that integrates microfluidic sensors, machine learning, and aptamers, Chronus is poised to be the first to successfully deliver a platform capable of testing multiple blood panels outside the central lab setting. With 60% of all blood tests conducted outside hospitals, the company is at the forefront of providing fast and accurate blood testing at the point of care, at a lower price point.

“No one likes waiting for blood test results – neither doctors nor patients or their families,” said Caesar Djavaherian, MD, Co-Founder and Chief Clinical Innovation Officer of Carbon Health. “Now we have a technology that can cost-effectively provide results at the point of care, leading to better patient outcomes and increased provider satisfaction. We look forward to launching a clinical trial using the Chronus system soon.”

“We are creating a new era for point-of-care testing, with a platform slated to revolutionize the diagnostics industry,” said Anand Parikh, CEO and Co-Founder of Chronus Health. “The foundation of processing lab work has remained the same for decades, and just as other industries have benefited from the innovation in electrical technology, so too will healthcare.”

Related Links:
Chronus Health

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more